1. Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.
- Author
-
Lewandowski, Cutler T., Maldonado Weng, Juan, and LaDu, Mary Jo
- Subjects
- *
AMYLOID plaque , *ALZHEIMER'S disease , *TRANSGENIC mice , *PATHOLOGY , *APOLIPOPROTEIN E , *ANIMAL models in research - Abstract
The focus on amyloid plaques and neurofibrillary tangles has yielded no Alzheimer's disease (AD) modifying treatments in the past several decades, despite successful studies in preclinical mouse models. This inconsistency has caused a renewed focus on improving the fidelity and reliability of AD mouse models, with disparate views on how this improvement can be accomplished. However, the interactive effects of the universal biological variables of AD, which include age, APOE genotype, and sex, are often overlooked. Age is the greatest risk factor for AD, while the ε4 allele of the human APOE gene, encoding apolipoprotein E, is the greatest genetic risk factor. Sex is the final universal biological variable of AD, as females develop AD at almost twice the rate of males and, importantly, female sex exacerbates the effects of APOE4 on AD risk and rate of cognitive decline. Therefore, this review evaluates the importance of context for understanding the role of APOE in preclinical mouse models. Specifically, we detail how human AD pathology is mirrored in current transgenic mouse models ("What") and describe the critical need for introducing human APOE into these mouse models ("Who"). We next outline different methods for introducing human APOE into mice ("How") and highlight efforts to develop temporally defined and location-specific human apoE expression models ("When" and "Where"). We conclude with the importance of choosing the human APOE mouse model relevant to the question being addressed, using the selection of transgenic models for testing apoE-targeted therapeutics as an example ("Why"). Unlabelled Image • What: AD is uniquely human, but molecular mechanisms can be measured in Tg mice. • Who: A universal biological variable of AD, APOE is critical for preclinical models. • How: There are several strategies for developing APOE -Tg mice. • When/Where: Developmental and region-specific models probe apoE expression patterns. • Why: Therapeutic strategies targeting apoE can exploit the relevant mouse model(s). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF